Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO), a biotechnology company focused on Klotho-based therapeutics for neurodegenerative diseases, announced its CEO Dr. Joseph Sinkule will attend the Inaugural Klotho Conference & Scientific Seminar. The event will be held at UC-Irvine Beal Applied Innovation Center from September 15-16, 2025.

The company's scientific advisors, Dr. Miguel Chillon and Dr. Assumpcio Bosch, will present their research on Klotho gene therapy for treating ALS, Alzheimer's and longevity. Investors and potential partners interested in meeting with Dr. Sinkule during the conference can contact ir@klothoneuro.com.

NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, announces CEO and Chairman Dr. Joseph Sinkule will attend the Inaugural Klotho Conference & Scientific Seminar. The event, the first ever conference on the future of klotho-based therapies and diagnostics, will be held at the UC-Irvine Beal Applied Innovation Center in Irvine, Calif. September 15-16, 2025.

The Company's two key scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch will be presenting their research achievements exploring Klotho gene therapy in the treatment of ALS, Alzheimer's and longevity.

Dr. Sinkule will be available to meet with investors and potential partners during the conference. Interested parties can contact ir@klothoneuro.com. 

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. KLOTHO is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Contact and Corporate Communications:
Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-ceo-to-attend-inaugural-conference--scientific-seminar-302548238.html

SOURCE Klotho Neurosciences, Inc.

FAQ

When and where is the Inaugural Klotho Conference & Scientific Seminar 2025?

The conference will be held on September 15-16, 2025 at the UC-Irvine Beal Applied Innovation Center in Irvine, California.

What will be presented at the Klotho Neurosciences (KLTO) conference?

Scientific advisors Dr. Miguel Chillon and Dr. Assumpcio Bosch will present their research on Klotho gene therapy for treating ALS, Alzheimer's, and longevity.

How can investors meet with Klotho Neurosciences CEO during the conference?

Investors and potential partners can contact ir@klothoneuro.com to schedule meetings with CEO Dr. Joseph Sinkule during the conference.

What diseases is Klotho Neurosciences (KLTO) targeting with their therapeutics?

Klotho Neurosciences is developing Klotho-based therapeutics for neurodegenerative diseases, specifically focusing on ALS and Alzheimer's.